Arena Pharma links with Ildong for Belviq marketing in South Korea

8 November 2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) has entered into a marketing and supply agreement with Ildong Pharmaceutical for its weight loss drug Belviq (lorcaserin HCl), granting the South Korean firm exclusive rights to market and distribute the product in South Korea for weight loss or weight management in obese and overweight patients, subject to regulatory approval of Belviq by the Korea Food and Drug Administration (KFDA).

"We are continuing to execute on our vision to broaden the availability of Belviq for patients and physicians by establishing collaborations that support the drug's development, approval and commercialization in additional territories worldwide," said Jack Lief, Arena's president and chief executive.

Upfront $5 million and $3 million on KFDA approval for Arena

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK